




DOCKET NO: B00192.70034.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Elma Tchilian, et al.
Serial No.: 10/020,758
Confirmation No.: 8645
Filed: October 30, 2001
For: SCREENS FOR SUSCEPTIBILITY TO
IMMUNODEFICIENCY AND VIRAL DISEASE
Examiner: Sally A. Sakelaris
Art Unit: 1634

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 25th day of July, 2003.


Melissa L. Barlow

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

690776.1

07/30/2003 SSESHE1 00000073 10020758

01 FC:1806

180.00 0P

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.


Respectfully submitted,
Elma Tchilian, et al., *Applicant(s)*

By: 
Mary Dilys S. Anderson, Ph.D., Reg. No. 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. B00192.70034.US

Date: July 25, 2003

XNDDX



FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/020,758		ATTY. DOCKET NO.: B00192.70034.US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 30, 2001		CONFIRMATION NO.: 8645	
				APPLICANT: Elma Tchilian, et al.			
				GROUP ART UNIT: 1634		EXAMINER: Sally A. Sakelaris	
Sheet	1	of	3				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	AKBAR, A. N., et al., "Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells." 1988. J. Immunol., 140: 2171-2178.		
	C2	ARICO, M., et al., "Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene." 2001. Blood, 97:1131-1133.		
	C3	BRYANT A, et al., "Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2." 1990. Clin Immunol Immunopathol; 56: 239-248.		
	C4	BUJAN, W., et al., "Abnormal T-cell phenotype in familial erythrophagocytic lymphohistiocytosis." 1993. Lancet, 342:1296.		
	C5	BYTH, K. et al., "CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and in B cell maturation." 1996. J. Exp. Med., 183(4):1707-1718.		
	C6	DREYER, Z. E., et al., "Infection-associated hemophagocytic syndrome. Evidence for Epstein-Barr virus gene expression." 1991. Am. J. Pediatr. Hematol. Oncol., 13:476-481.		
	C7	DUFOURCQ-LAGELOUSE, R., et al., "Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity" 1999. Am. J. Hum. Genet., 64:172-179.		
	C8	FANNING, G.C. et al., "Polymerase chain reaction haplotyping using 3' mismatches in the forward and reverse primers: application to the biallelic polymorphisms of tumor necrosis factor and lymphotoxin α ." 1995. Tissue Antigens, 50:23-31.		
	C9	GENBANK Accession Number M23461 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exons 1 and 2, 11-FEB-2002.		
	C10	GENBANK Accession Number M23462 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 3, 11-FEB-2002.		
	C11	GENBANK Accession Number M23466 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 7, 11-FEB-2002.		
	C12	GENBANK Accession Number M23467 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 8, 11-FEB-2002.		
	C13	GENBANK Accession Number M23468 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 9 11-FEB-2002.		

JUL 28 2003

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C14	GENBANK Accession Number M23469 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 10, 11-FEB-2002.	
	C15	GENBANK Accession Number M23470 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 11, 11-FEB-2002.	
	C16	GENBANK Accession Number M23471 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 12, 11-FEB-2002.	
	C17	GENBANK Accession Number M23472 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 13, 11-FEB-2002.	
	C18	GENBANK Accession Number M23473 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 14, 11-FEB-2002.	
	C19	GENBANK Accession Number M23474 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 15, 11-FEB-2002.	
	C20	GENBANK Accession Number M23475 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 16, 11-FEB-2002.	
	C21	GENBANK Accession Number M23476 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 17, 11-FEB-2002.	
	C22	GENBANK Accession Number M23477 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 18, 11-FEB-2002.	
	C23	GENBANK Accession Number M23478 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 19, 11-FEB-2002.	
	C24	GENBANK Accession Number M23479 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 20, 11-FEB-2002.	
	C25	GENBANK Accession Number M23480 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 21, 11-FEB-2002.	
	C26	GENBANK Accession Number M23481 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 22, 11-FEB-2002.	
	C27	GENBANK Accession Number M23482 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 23, 11-FEB-2002.	
	C28	GENBANK Accession Number M23483 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 24, 11-FEB-2002.	
	C29	GENBANK Accession Number M23484 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 25, 11-FEB-2002.	
	C30	GENBANK Accession Number M23485 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 26, 11-FEB-2002.	
	C31	GENBANK Accession Number M23486 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 27 11-FEB-2002.	
	C32	GENBANK Accession Number M23487 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 28, 11-FEB-2002.	
	C33	GENBANK Accession Number M23488 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 29, 11-FEB-2002.	
	C34	GENBANK Accession Number M23489 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 30, 11-FEB-2002.	
	C35	GENBANK Accession Number M23490 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 31, 11-FEB-2002.	
	C36	GENBANK Accession Number M23491 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 32, 11-FEB-2002.	
	C37	GENBANK Accession Number M23492 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 33 and partial cds, 11-FEB-2002.	
	C38	GENBANK Accession Number M23494 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 4, 11-FEB-2002.	
	C39	GENBANK Accession Number M23495 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 5, 11-FEB-2002.	
	C40	GENBANK Accession Number M23496 Homo sapiens T200 leukocyte common antigen precursor (PTPRC) gene, exon 6, 11-FEB-2002.	



Examiner Initials	Cite	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C41	IRIE-SASAKI, J., et al., "CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling" 2001. Nature, 409:349-354.	
	C42	JACOBSEN, M., et al., "A point mutation in PTPRC is associated with the development of multiple sclerosis." 2000. Nature Genetics, 26:495-499.	
	C43	JANKA, G. E. "Familial hemophagocytic lymphohistiocytosis" 1983. Eur. J. Pediatr., 140:221-230.	
	C44	KISHIHARA, K. et al., "Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice." 1993. Cell, 74:143-156.	
	C45	KOZIERADZKI, I., et al., "T cell development in mice expressing splice variants of the protein tyrosine phosphatase CD45." 1997. J. Immunol., 158:3130-3139.	
	C46	KUNG, C. et al., "Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease." 2000. Nature Medicine, 6: 343-345.	
	C47	LYNCH, K. W. et al., "A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer." Jun 29 2001. J Biol Chem., 276(26):24341-24347.	
	C48	MISBAH S.A. et al., "Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia." 1991. Postgrad Med J, 67: 301-303.	
	C49	OMIM accession 151460. "Protein-tyrosine phosphatase, receptor-type, c; PTPRC: Severe combined immunodeficiency due to ptpc deficiency, included." Gene map locus 1q31-q32, pp 1-9.	
	C50	RUDGE P, et al., "Encephalomyelitis in primary hypogammaglobulinaemia." 1996. Brain, 119:1-15.	
	C51	SAGA, Y. et al., "Sequences of Ly-5 cDNA: Isoform-related diversity of Ly-5 mRNA." 1986. Proc. Natl. Acad. Sci. USA, 83:6940-6944.	
	C52	SCHAFER, A. J. et al., "DNA variation and the future of human genetics." 1998. Nature Biotechnology, 16:33-39.	
	C53	SCHWINZER, R. et al., "Genetically determined lack of CD45R ⁺ T cells in healthy individuals: Evidence for a regulatory polymorphism of CD45R antigen expression." 1990. J. Exp. Med., 171:1803-1808.	
	C54	STREULI, M. et al., "Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens." 1987. J. Exp. Med., 166:1548-1566.	
	C55	TCHILIAN, E.Z. et al., "A deletion in the gene encoding the CD45 antigen in a patient with SCID." 2001. J. Immunol., 166:1308-1313.	
	C56	TCHILIAN, E.Z. et al., "The exon A (C77G) mutation is a common cause of abnormal CD45 splicing in humans." 2001. J Immunol; 166:6144-6148.	
	C57	THUDE, H. et al., "A point mutation in the human CD45 gene associated with defective splicing of exon A." 1995. Eur J Immunol, 25(7):2101-2106.	
	C58	TROWBRIDGE, I. S. et al., "CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development." 1994. Ann. Rev. Immunol., 12:85-116.	
	C59	WAGNER, R., et al., "A prospective study of CD45 isoform expression in haemophagocytic lymphohistiocytosis; an abnormal inherited immunophenotype in one family" 1995. Clin. Exp. Immunol., 99:216-220.	
	C60	ZILCH, C. F., et al., "A point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans." 1998. Eur. J. Immunol., 28:22-29.	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]